Lazard Asset Management LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Lazard Asset Management LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 60.4% in the 1st quarter, HoldingsChannel reports. The firm owned 16,280 shares of the biopharmaceutical company’s stock after purchasing an additional 6,128 shares during the quarter. Lazard Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $5,387,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $895,816,000. Qube Research & Technologies Ltd purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $369,943,000. AQR Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 295.2% during the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after acquiring an additional 555,759 shares in the last quarter. Orbis Allan Gray Ltd grew its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Alnylam Pharmaceuticals by 2,221.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company’s stock valued at $187,116,000 after acquiring an additional 392,668 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter adjusted EPS of $1.84, above the $1.63 consensus estimate, while revenue rose 66.9% year over year to $1.29 billion. The company also highlighted strong demand and performance from its TTR medicines. Alnylam Q2 2026 Earnings Call Shows TTR Strength
• Positive Sentiment: Needham lowered its price target to $357 from $510 but maintained a Buy rating, indicating that the analyst still sees substantial long-term upside despite the revised near-term outlook. Benzinga
• Neutral Sentiment: The company forecast 2026 revenue of $5.3 billion to $5.7 billion, versus analyst expectations of approximately $5.6 billion. The range remains broadly near consensus, but the lower end signals reduced confidence in the pace of growth.
• Negative Sentiment: Alnylam lowered its fiscal 2026 guidance as demand for second-line use of Amvuttra normalized. Investors appear more focused on the weaker forward outlook and potential moderation in commercial momentum than on the quarterly EPS beat. Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
• Negative Sentiment: A shareholder-rights law firm announced an investigation into possible securities-law violations. Although the announcement does not establish wrongdoing, it adds legal and reputational uncertainty following the guidance reduction. Securities Fraud Investigation Into Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $205.48 on Friday. The company has a market cap of $27.43 billion, a price-to-earnings ratio of 56.14 and a beta of 0.27. The firm’s fifty day moving average is $289.80 and its 200 day moving average is $312.07. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the company posted ($0.44) EPS. The business’s revenue was up 96.4% on a year-over-year basis. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current fiscal year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. cut their price objective on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, HC Wainwright increased their price target on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $445.48.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.